Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2025), N Engl J Med, 392, 777 - 787
The prevention and management of chronic kidney disease among patients with metabolic syndrome.
Zhu D. et al, (2025), Kidney Int
Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease.
Zhu D. et al, (2025), Nephrol Dial Transplant, 40, i70 - i79
ALDOSTERONE SYNTHASE INHIBITION WITH VICADROSTAT (BI 690517) TO REDUCE RISKS OF KIDNEY AND CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: A RATIONALE FOR THE EASi-KIDNEY TRIAL
Judge P. et al, (2024), Nephrology Dialysis Transplantation
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129
Cohort Profile: Indian Study of Healthy Ageing (ISHA- Barshi)
BRAGG F. et al, (2024), International Journal of Epidemiology
Improvements in Kidney Outcomes Over the Years: Reason for Optimism but a Challenge for Trialists.
Zhu D. et al, (2024), Am J Kidney Dis, 83, 427 - 428
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2024), Lancet Child Adolesc Health, 8, 190 - 200
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.
Mayne KJ. et al, (2024), J Am Soc Nephrol, 35, 202 - 215
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None. et al, (2024), Nat Commun, 15
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 39 - 50
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 51 - 60
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2023), Lancet Diabetes Endocrinol, 11, 905 - 914
A versatile approach to high-density microcrystals in lipidic cubic phase for room-temperature serial crystallography.
Birch J. et al, (2023), J Appl Crystallogr, 56, 1361 - 1370
Sacubitril/valsartan in peritoneal dialysis-lessons from a pharmacokinetic study.
Judge PK. et al, (2023), 38, 1780 - 1781
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk None. and RECOVERY Collaborative Group None., (2023), Lancet, 401, 1499 - 1507
Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.
Chapman D. et al, (2023), Kidney Int, 103, 787 - 790
Empagliflozin in Patients with Chronic Kidney Disease.
The EMPA-KIDNEY Collaborative Group None. et al, (2023), N Engl J Med, 388, 117 - 127